NEW YORK (GenomeWeb News) – Dow AgroSciences and Chromatin announced this week that they have struck a pair of agreements. The first provides Dow AgroSciences, a subsidiary of Dow Chemical Company, the rights to Chromatin's "mini-chromosome" genetic elements for delivering specific traits into plant cells. The second establishes an exclusive research and license agreement to combine Dow's EXZACT Precision genome-modification technology with mini-chromosomes, creating a technology platform to develop next-generation traits in corn, soybeans, and canola.
OriGene Technologies said this week that the Royal Institute of Technology in Sweden has adopted its VERIFY Tagged Antigen in the Human Protein Atlas program. The program, funded by the Knut and Alice Wallenberg Foundation, aims to explore the human proteome systematically using antibody-based proteomics. OriGene's VERIFY Tagged Antigens are over-expression lysates that can be used to validate antibody and biomarker discovery.
Duke University and India's Jubilant Organosys inked a letter of intent to jointly expedite translation of discoveries by Duke scientists into clinical therapies. Under the partnership, Duke researchers will work with scientists from Jubilant Organosys' drug-discovery subsidiary, Jubilant Biosys, to select and manage a portfolio of translational research projects over a period of five years. In addition, Jubilant and Duke will collaborate on two biomarker studies to be conducted in Kolkata, India. One study aims to develop a cohort to gain insights into clinical and molecular characteristics of several chronic diseases that are highly prevalent in the Indian population. The second study will validate in an Indian population metabolomic biomarker signatures found to be associated with insulin resistance and cardiovascular disease in Caucasian populations.
Pacific Biosciences will use the CamStar Manufacturing enterprise software platform to enable its transition from product development to high-volume production and ensure quality control, CamStar Systems said this week. Pacific Bio has developed a technology called Single Molecule Real Time Biology, which it is using it to develop commercial DNA sequencing applications.